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Abstract
Macrophage migration inhibitory factor (MIF) is a homotrimeric multifunctional proinflammatory
cytokine that has been implicated in the pathogenesis of several inflammatory and autoimmune
diseases. Current therapeutic strategies for targeting MIF focus on developing inhibitors of its
tautomerase activity or modulating its biological activities using anti-MIF neutralizing antibodies.
Herein we report a new class of isothiocyanate (ITC)-based irreversible inhibitors of MIF.
Modification by benzyl isothiocyanate (BITC) and related analogues occurred at the N-terminal
catalytic proline residue without affecting the oligomerization state of MIF. Different alkyl and
arylalkyl ITCs-modified MIF with nearly the same efficiency as BITC. To elucidate the
mechanism of action, we performed detailed biochemical, biophysical, and structural studies to
determine the effect of BITC and its analogues on the conformational state, quaternary structure,
catalytic activity, receptor binding and biological activity of MIF. Light scattering, analytical
ultracentrifugation and NMR studies on unmodified and ITC-modified MIF demonstrated that
modification of Pro1 alters the tertiary, but not the secondary or quaternary, structure of the trimer
without affecting its thermodynamic stability. BITC induced drastic effects on the tertiary
structure of MIF, in particular residues that cluster around Pro1 and constitute the tautomerase
active site. These changes in tertiary structure and loss of catalytic activity translated into
reduction in MIF receptor binding activity, MIF-mediated glucocorticoid overriding and MIF-
induced Akt phosphorylation. Together, these findings highlight the role of tertiary structure in
modulating the biochemical and biological activities of MIF and present new opportunities for
modulating MIF biological activities in vivo.
Macrophage migration inhibitory factor (MIF) is a multifunctional protein that is now
recognized as a major player in innate immune responses and regulation of the host response
to inflammation and infection. MIF is expressed in a variety of cells and has been implicated
in a wide range of cellular activities, including transcriptional regulation of inflammatory
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gene products (1), regulation of glucocorticoid activity (2), cell cycle control by promoting
cell proliferation and survival through activation of the ERK1/2 MAPKs (3), the inhibition
of the p53 and retinoblastoma/E2F tumor suppressor pathways (4, 5) and the activation the
phosphoinositide-3-kinase (PI3K)/Akt survival pathway (6). Several lines of evidence
support a central role for MIF in the pathogenesis of inflammatory and autoimmune diseases
including arthritis (7, 8), glomerulonephritis (9, 10), diabetes (11, 12) , colitis (13), sepsis
(14-18), acute respiratory distress syndrome (19, 20) and cancer (21-23). Therefore,
targeting MIF activity has emerged as a viable therapeutic approach for treating these
inflammatory and autoimmune diseases.
In addition to its reported biological activities, MIF is known to catalyze the tautomerization
of phenylpyruvate (or hydroxy-phenylpyruvate) and D-dopachrome methyl ester (Figure 1)
(24-27). Although the physiological substrates of MIF remain unknown, and the exact
relationship between its catalytic activity and biological function is still not well understood,
targeting MIF tautomerase activity using small-molecule inhibitors has emerged as a viable
strategy for inhibiting MIF proinflammatory activity and attenuating its biological activity in
vitro and in vivo (28-30). The first example of a small molecule MIF inhibitor was NAPQI,
which was described by Senter et al. to form a covalent complex with the MIF catalytic
proline residue (Pro1) (Figure 1), thereby eliminating tautomerase activity. NAPQI-modified
MIF failed to override the immunosuppressive effect of dexamethasone on LPS-induced
TNF production by monocytes, but has not been tested in the clinic due to its potential
toxicity (31). Al-Abed and co-workers subsequently developed several active site inhibitors
based on modifications of the scaffold of (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-
isoxazole acetic acid methyl ester (ISO-1) (32, 33). MIF tautomerase inhibitors, including
ISO-1, phenolic hydrazone (34), OXIM-11 (29), and COR10014 (30) were shown to have
protective effects in animal models of sepsis and RA. Inhibition of MIF tautomerase activity
by these molecules was also accompanied by modulation of its biological activities,
including inhibition of 1) MIF glucocorticoid overriding activity; 2) endotoxin (LPS)-
induced TNF production, and MIF-mediated i) stimulation of ERK1/2 MAP kinase and
proliferation of serum starved cells (33), ii) upregulation of arachidonic acid in
macrophages, and iii) Cox-2 activation.
Herein we report a new class of ITC-based irreversible inhibitors of MIF. To elucidate their
mechanism of action, we performed detailed biochemical, biophysical and structural studies
to determine their effect on the conformational state, quaternary structure, enzymatic
activity, receptor binding and biological properties of MIF. These studies demonstrate that
in addition to blocking the catalytic activity of MIF, selective modification of Pro1 alters the
tertiary structure of MIF and results in significant reduction in MIF-mediated glucocorticoid
overriding and MIF-induced Akt phosphorylation. These findings and their implication for
therapeutic strategies targeting MIF are presented and discussed.
MATERIALS AND METHODS
Chemicals
Benzyl isothiocyanate (BITC), allyl isothiocyamate (AITC), ethyl isothiocyanate (EITC),
methallyl Isothiocyanate (MITC), 2-Piperidinoethyl isothiocyanate (2PITC), cyclopropyl
isothiocyanate (CPITC) and Phenylethyl isothiocyanate (PEITC) were purchased from
Sigma or Fluka and were of the highest purity available.
Expression and purification of human MIF
MIF protein was expressed by heat shock transformation of the BL21DE3 E. coli strain
(Stratagene) with bacterial expression vector pET11b containing the human MIF gene under
Ouertatani-Sakouhi et al. Page 2
Biochemistry. Author manuscript; available in PMC 2013 March 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
control of the T7 promoter. Four h post-induction, the cells were harvested, resuspended in
lysis buffer (50 mM TRIS, 50 mM KCl, 5 mM MgAc, 0.1 % azide), sonicated at 200 Hz
pulse repetition frequency for 20 min using a VibraCellTM sonicator, and harvested by
centrifugation at 13000g for 25 min. The clarified cell lysate was filtered, injected onto a
MonoQ anion exchange column (HiPrep ™ 16/10 Q FF GE Healthcare), and eluted with a
linear NaCl gradient in the elution buffer (25 mM Tris HCl pH 7.4, 150 mM NaCl). The
flow-through fractions containing MIF were pooled and loaded onto a Superdex 75 16/60
(HiLoad™ 16/60, Superdex™ 75, Pharmacia Biotech) gel filtration column. Fractions
corresponding to MIF were pooled together, dialyzed against PBS, and filtered. The identity
and purity of the protein was confirmed by MALDI-TOF mass spectrometry, silver staining,
and western blotting using the rabbit anti-MIF antibody from Zymed (Ivitrogen) at 1:20000.
When required, the proteins were concentrated using a concentrator with a MWCO of 5 kDa
and stored at 4 °C until use. Uniformly 15N-labeled protein samples were prepared for NMR
experiments by culturing the bacteria in M9 minimal medium containing 15N-ammonium
chloride (1 g/L) as the only nitrogen source. Recombinant MIF used for cellular studies was
subjected to LPS removal as described previously (35). Briefly, Bacterial cell lysate was
injected to anion exchange column and the flow-through fractions containing MIF were
applied to C8-Seppak cartridge and MIF was eluted with 60% acetonetrile/water,
lyophilized and renaturated. The LPS content was quantified using chromogenic Limulus
amoebocyte assay.
Analytical ultracentrifugation (AUC)
Analytical ultracentrifugation experiments were performed using purified and dialyzed MIF
samples (10-20 μM) preincubated with BITC for 1 h at an MIF concentration corresponding
to 100% inhibition. Radial UV scans were recorded on a Beckman Optima XL-A at a
wavelength of 277 nm. Sedimentation velocity experiments were carried out at 20 °C using
380-400 μl of protein solution. Data were recorded at rotor speeds of 50000 rpm in
continuous mode, with a step size of 0.003 cm. The experimentally determined partial
specific volume of 0.765 mg/ml was used to calculate the molecular weights of MIF (36).
The sedimentation velocity profiles were analyzed as a c(s) distribution of the Lamm
equation using SEDFIT. Molar mass distributions c(M) were obtained by transforming the
corresponding c(s) using SEDFIT.
Analytical size exclusion chromatography and light scattering
Size exclusion chromatography experiments were performed on purified MIF incubated in
the presence and absence of BITC or its analogues using an analytical Superdex 75 10/30
column at room temperature. The column was equilibrated with 10 mM Tris buffer (pH 7.6),
and MIF samples (12 μM in PBS 1X) in volumes of 0.5 mL were injected onto the column
and eluted at a flow rate of 0.4 mL/min in a Agilant HPLC system attached to both UV,
refractive index and .DAWN HELLIOS multiangle light scattering detector (Wyatt
Technology Corp, Santa Barbara CA). Absolute MWs were determined using ASTRA
version 5.3 from Wyatt Technologies.
MALDI-TOF-MS MW measurements to examine possible protein modifications
Matrix Assisted LASER Desorption Ionization-Time of Flight-Mass Spectrometry
(MALDI-TOF-MS) was performed to examine any HITS-induced protein modification. The
matrix solution was prepared by dissolving 14 mg/ml of sinapinic acid (SA) solution in
0.1% TFA/ACN (1/1). A thin matrix layer was generated on the mirror-polished target using
a gel loading tip. One microliter of sample (15 μM MIF incubated with 10 μM HITS for 1h)
was mixed with 1 μl of SA matrix solution, and 0.8 μl of this mixture was deposited on top
of the thin layer and allowed to air dry. The samples were analyzed with a 4700 MALDI-
TOF/TOF instrument (Applied Biosystems).
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Protein digestion analysis to identify the modified residue
One microliter of MIF sample previously incubated for 1 h with BITC 10μM, was diluted in
5 μl of 100 mM BA and digested overnight with trypsin (Promega). The digestion was
stopped with 1 μl of 10% TFA and stored at 4 °C until further use. The samples were
analyzed by MALDI-MS on a 4700 MALDI-TOF/TOF instrument (Applied Biosystems) or
an Axima CFR plus instrument (Shimadzu) without further purification. One microliter of
sample was mixed with 1 μl of DHB (20 mg/ml in 1%PA/ACN (1/1)), and 0.8 μl of this
mixture was deposited on the target and allowed to air dry. MALDI matrices and calibrants
were obtained from Sigma/Fluka (Schnelldorf, Germany), TFA was from Pierce, and SA
and 2,5-dihydroxybenzoic acid (DHB) were from Fluka. Cytochrome C and apomyoglobin
were from Sigma
Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR spectra were acquired at 27°C on a Bruker Avance 600 MHz NMR spectrometer
using a triple-resonance cryoprobe equipped with z-axis self-shielded gradient coils.
Measurements were performed using 100-200 μM samples. All samples were prepared in 20
mM Na2HP04, 0.5 mM EDTA, 0.02% NaN3 (pH 7.0), and 10% D2O. Two-
dimensional 1H-15N heteronuclear single quantum coherence (HSQC) spectra were recorded
using 256 × 1024 complex data points in the F1 and F2 dimensions, with a relaxation delay
of 1.0 s. Sixty-four scans per increment were recorded for each spectrum. Spectral widths
were 2200 and 8950 Hz in the 15N and 1H dimensions, respectively. Specifically,
2D 1H-15N HSQC spectra were recorded to follow chemical shift changes upon addition of
inhibitory compounds and to map the interaction surface of MIF for each compound. For
this, a reference spectrum of MIF alone was recorded in the presence of 1% DMSO. For
each titration step of MIF with inhibitory compounds, a new sample was prepared in which
MIF was mixed with the corresponding compound dissolved in DMSO, with the DMSO
concentration maintained at 1%.
Spectra were processed with Topspin (Bruker) and NMRPipe (37). Visualization and
manipulation were performed using the public domain graphics program Sparky 3 [Goddard
TD, Kneller DG (2004) SPARKY 3. University of California, San Francisco]. Resonance
assignments were previously published for the same buffer system at 30°C (38). The
addition of 1% DMSO and a small change in temperature did not interfere with the transfer
of resonance assignment. Both intensity and chemical shift differences were analyzed with
respect to the reference spectrum. Mean weighted 1H-15N chemical shift differences were
calculated according to Δδ = {[(Δδ1H)2 + ((Δδ15N)/5)2 ]1/2}/2 (39). Changes were mapped
on the crystal structure using the PDB file 1GDO (1.5 Å resolution) and PyMOL software.
MIF receptor binding assay
Recombinant, soluble huMIF receptor ectodomain (sCD7473-232) was cloned and purified as
described by (40) and used to coat 96 well plates by incubation at 4°C overnight. Plates were
washed 4 times with TTBS (pH 7.4) and blocked with superblock buffer (PIERCE) for 1 h
at room temperature. Biotinylated huMIF (Roche Molecular Biochemical) was prepared and
added together in triplicate wells with increasing concentrations of purified huMIF trimer
(35), heat-denatured huMIF, or test MIF proteins. Incubation was at room temperature for 2
h. After washing wells 4 times with TTBS (pH 7.4), streptavidin-conjugated alkaline
phosphatase (R&D) was added, incubation continued for an additional h, and the wells
washed and bound complexes detected by adding p-nitrophenyl phosphate (Sigma).
Absorbance was read at 405 nm using a DYNATECH, MR5000 plate reader, and values
plotted as percent OD405 relative to wells containing biotinylated-MIF alone. The plots
shown are representative of at least three assays, and each plotted point depicts a SEM ≤ 10
%.
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Glucocorticoid overriding assay
PBMCs from healthy donors (recruited by the Blood Center, Lausanne, Switzerland) were
purified by Ficoll-Hypaque density gradient (GE Healthcare). To obtain macrophages,
adherent PBMCs (106 cells per well in 48-well plates) were cultured for 6 days in RPMI
1640 with Glutamax. Media were supplemented with 10% heat-inactivated FCS (Seromed)
and antibiotics. MIF was incubated with the inhibitors for 15 min at room temperature.
Primary macrophages were pre-incubated for 1 h with 100 nM dexamethasone,
dexamethasone plus MIF (100 ng/mL) or dexamethasone plus MIF and BITC (10 μM)
before the addition of 100 ng/ml Salmonella minnesota Ultra Pure LPS (List Biologicals
Laboratories). TNF concentrations in cell-culture supernatants collected after 4 h were
measured by bioassay. Statistical analyses were performed using one way Anova followed
by Scheffè’s test for BITC treatment from 4 independent experiments. A significance of p <
0.05 was required for rejection of the null hypothesis.
Phospho Akt activation by MIF
Confluent HeLa cells were incubated for 2 h with recombinant human MIF (50 ng/mL) in
the presence of BITC, LY294002 (10 and 1 μM) or DMSO. Phosphorylation of Akt (Ser
473) was measured using Alpha screen SureFire phosphokinase KIT, an immunosandwich
assay based on alpha screen technology in two incubation steps, according to the
manufacturer’s protocol. First, cell lysate was incubated for 2 h with an anti-Akt antibody
captured to protein A conjugated acceptor beads. Then, the biotinylated anti pAkt antibody
was added with streptavidin coated Alpha donor beads. The two beads are brought in close
proximity only in the presence of phosphorylated Akt. Up on illumination at 680 nm, alpha
donor beads photosensitizer, converts the ambient oxygen to an excited form, which will
enable the excitation of the alpha acceptor beads. Data are reported as alpha screen counts.
Statistical analyses were performed using one way Anova followed by Scheffè’s test for
compound treatment from 3 independent experiments. A significance of p < 0.05 was
required for rejection of the null hypothesis.
RESULTS
Benzyl isothiocyanate (BITC) inhibits MIF tautomerase activity
During our screening for inhibitors of MIF tautomerase activity we observed that BITC
demonstrated 100% inhibition of the tautomerase activity of both human and murine MIF at
concentrations of 10 μM . We hypothesized that this inhibitory activity is due to the
reactivity of the isothiocyanate group in BITC. To test this hypothesis we evaluated the
inhibitory effect of several ITCs at concentrations ranging from 0-100 μM and obtained the
following IC50 values 0.79, 3.69, 11.10, 1.43, 3.09 μM, for BITC, AITC, EITC, MITC, and
2PITC (Figure 2).
BITC mode of action
Inhibition of MIF’s tautomerase activity can occur via at least five different mechanisms: 1)
binding to the active site; 2) allosteric inhibition; 3) covalent modification of active site
residues; 4) disruption of the active site through compound-induced dissociation of the
active trimer; and 5) stabilization of the MIF monomer and prevention of its re-association
to form the active trimer. To elucidate the mechanism of action BITC we performed detailed
biochemical, biophysical, and structural studies to determine the effect of BITC and its
analogues on the conformational state, quaternary structure, catalytic activity, receptor
binding and biological activity of MIF.
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BITC inhibition of MIF tautomerase activity is mediated by selective modification of the N-
terminal proline
BITC contains the isothiocyanate reactive group which can readily interact with O-, S- or N-
based nucleophiles. As a result, BITC may react with cysteine residues (41, 42) or with the
N-terminus of the protein, as in the case of phenyl isothiocyanate (PITC; Ph-N=C=S) used
in protein sequencing using Edman degradation. This raised the possibility that BITC
inhibition of MIF tautomerase activity might occur through covalent modification of MIF.
To test this, MIF (15 μM) in Tris buffer 50 mM pH 7.4 was incubated with BITC (10 μM)
for 60 min and the formation of a BITC-MIF adduct was monitored by MALDI-TOF mass
spectrometry. Under these conditions, a shift in the monomeric molecular mass of MIF by
148.33 mass units from 12345.16 to 12493.50 was observed, which corresponds to the
addition of one molecule of BITC. At concentrations > 10 μM, we observed complete
conversion to the singly modified form of MIF, consistent with a single site modification by
BITC (Figure 3A, Figure S1).
To identify the site of covalent modification, the BITC-modified MIF was subjected to
proteolytic digestion by trypsin and peptide mapping by mass spectrometry. Tryptic
digestion of BITC modified MIF (Figure 3A) revealed a fragment peptide with a m/z ratio of
1436.70, which corresponds to the N-terminal fragment (PMFIVTNTNVPR, m/z = 1287.61)
plus one molecule of BITC (Figure 3B). This fragment is devoid of any nucleophilic residue
(lysines and cysteines) that may react with ITCs, except for the N-terminal proline. MS/MS
analysis of this peptide fragment demonstrated that BITC modification takes place at the N-
terminal proline residue. Six additional ITC analogues, AITC, EITC, MITC, 2PITC, CPITC
and PEITC were also tested and all were shown to modify MIF at the N-terminal Pro residue
(Figure 3C).
BITC modification is specific to MIF
BITC shares structural similarities with PITC, which is used in N-terminal polypeptide
sequencing, suggesting that its modification of MIF might not be specific. To assess this
possibility, different proteins were incubated with BITC and characterized by MALDI-TOF.
BITC was incubated with ubiquitin, lysozyme, or α-synuclein at equimolar concentrations
either for 1 h or overnight at RT. No modification was detected for either incubation time by
MS, suggesting that the reactivity with N-terminal proline is specific and likely due to its
altered pKa and increased nucleophilicity (Figure S2).
BITC modifies only catalytically active forms of MIF
Recent studies from our laboratory demonstrated that disrupting the conformation of the C-
terminus via truncation or insertion of secondary structure-disrupting elements (proline
residues) within the C-terminal region (residues 104-115) abolished the protein’s activity
without altering its oligomerization state. With these constructs at our disposal, we were
interested in further probing the specificity of BITC-induced modification of MIF by
determining whether BITC selectively modifies enzymatically active MIF. Six trimeric MIF
variants (3 enzymatically active: Wt, R73A, and N110C, and 3 inactive: R73AΔ5,
R73AΔ10, and P107) were tested by incubation with BITC. As expected, MALDI-TOF
analysis revealed total modification of the enzymatically active forms of MIF (Wt, N110C
and R73A), whereas no modification was observed for inactive MIF proteins (R73AΔ5,
R73AΔ10 or P107), suggesting that BITC modifies only catalytically active trimeric forms
of MIF (Figure 4).
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Modification by BITC and other ITCs does not alter the oligomerization state of MIF
To determine whether any of the ITCs functions by disrupting the MIF trimer, we compared
the quaternary structure distribution of MIF in the presence or absence of BITC (6 μM) by
sedimentation velocity analytical ultracentrifugation, size exclusion chromatography (SEC)
and light scattering (Figures 5 and 6). MIF preincubated either with DMSO as a control, or
BITC sedimented predominantly as a single species with a sedimentation coefficient and
molecular mass corresponding to that of the trimer (Figure 5). Previous studies from our
laboratory demonstrated that MIF elutes as two peaks in the SEC that correspond to two
different conformations of the trimers (43). The two different conformational states of the
trimer differ mainly in their tertiary structure. To determine if Pro1 modification by the ITCs
effects the distribution of the different trimers, we compared the elution profiles and
molecular weight distribution of MIF before after modification by ITCs by online SEC
coupled to a multi-angle light scattering detector. Figure 6 demonstrates that modification of
Pro1 by all active ITCs MIF inhibitors resulted in a shift in the elution profile of MIF. In
each case, the covalently ITC-modified MIF elutes as a single peak at 28 min, whereas the
unmodified MIF elutes as a mixture of two overlapping peaks (31 min and 33 min). The
light scattering results demonstrate that this shift in the SEC profile does not correspond to a
change in oligomerization state and is likely to be due to differences in tertiary structure
between the modified and the unmodified trimer forms of MIF. In each case, the ITC
modified MIF showed a molecular weight corresponding to the trimer. These findings
provide strong evidence in support of our hypothesis that the MIF trimer exists in different
conformational states.
Elucidating the structural basis for the inhibition of MIF enzymatic activity using NMR
In order to further elucidate the structural basis for the inhibition of MIF enzymatic activity,
NMR titrations were performed with BITC. Equimolar mixture of MIF with BITC results in
severe resonance broadening throughout the whole sequence, indicative of conformational
exchange. However, more drastic effects are seen for the residues 3-4, 32, 35-39, 49-50,
58-67, 79, 84-89, 95-97, 103, 107-109, and 112-114 (Figure 7A, 7B). The majority of these
residues cluster around P1 and are components of the active site (Figure 7C). Similar effects
had been previously observed in an NMR titration of MIF with HPP (44). Additionally, Y95
and N97 are components of the active site. Subunit interface is not as hydrophobic as the
interior of the monomer; however there is a hydrophobic patch on the surface. Residues
Y36, Y95, W108, F113 are a part of this patch.
Inhibitors of MIF tautomerase activity interfere with MIF binding to its receptor, CD74
A major cellular action of MIF is to inhibit activation-induced apoptosis by inducing
sustained MAP kinase (ERK1/2) activation (3, 23). MIF dependent ERK1/2 phosphorylation
proceeds by engagement of a two component receptor complex that comprises the binding
protein, CD74, and the signal initiating component CD44 (40, 45). Because the tautomerase
site has been implicated in receptor binding (31, 46), we tested the ability of selected
tautomerase inhibitors to inhibit MIF interaction with the soluble CD74 ectodomain
(CD7473-232 or sCD74) using an ELISA-based MIF “capture” assay (47). We tested the
potential inhibitory action of the N-terminal catalytic site modifier, BITC, as well as the
isothiocyante-based congeners, AITC, EITC, MITC, and 2PITC (Figure 8). With the
possible exception of 2PITC, these compounds showed no significant dose-dependent effect
at the concentrations tested, and inhibition plateaued at approximately 30-35%. Taken
together, these data suggest that that these compounds impart sufficient structural alterations
on MIF to influence its interaction with CD74.
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BITC inhibits MIF-mediated glucocorticoid overriding activity and enhancement of Akt
phosphorylation
Among the important in vivo immunoregulatory functions of MIF is its ability to counter-
regulate the immunosuppressive effect of glucocorticoids on proinflammatory cytokine
production (2). To examine whether BITC interferes the immunoregulatory function of MIF,
human macrophages were pretreated with dexamethasone (100 nM) with or without
recombinant MIF (100 ng/mL) and BITC (10 μM) prior to stimulation with LPS. Whereas
dexamethasone inhibited TNF production by LPS-stimulated monocytes, preincubation with
MIF overcame dexamethasone inhibition of TNF production (Figure 9A). Interestingly,
incubation of MIF with BITC before addition to dexamethasone abrogated MIF-mediated
dexamethasone overriding. It is noteworthy that BITC decreased TNF production even more
potently than dexamethasone, suggesting that BITC have anti-inflammatory activity is
independent of its effect on MIF structure and tautomerase activity (Figure 9A). Similar
results were obtained using the RAW 264.7 mouse macrophage cell line. To rule out the
possibility that the observed effects were due to BITC toxicity, we verified that BITC did
not alter macrophage viability under the culture conditions used to induce TNF production
(data not shown).
Previous studies have shown that MIF promotes cell survival through activation of the PI3K/
Akt pathway(48). The addition of recombinant MIF enhanced Akt phosphorylation via PI3K
in NIH3T3 and Hela cells (48). To determine whether BITC antagonized MIF-mediated Akt
phosphorylation, we quantified the level of phosphorylated Akt in HeLa cells cultured for 2
h with MIF (50 ng/mL) preincubated or not with BITC. As shown in Figure 9B, MIF
increased 1.5-fold phosphorylated Akt level in HeLa cells. BITC (1 and 10 μM) inhibited
MIF-induced Akt phosphorylation. The effect of BITC was specific for MIF, as BITC alone
did not modify baseline Akt phosphorylation in HeLa cells. PI3K selective inhibitor
LY294002, a known potent inhibitor of Akt was used as a control. Overall, these data
indicated that BITC was a powerful inhibitor of MIF biological activites.
DISCUSSION
Irreversible inhibition of MIF enzymatic activity via covalent modification of the N-terminal
catalytic proline (Pro1) has been described for several MIF inhibitors, including 2-oxo-4-
phenyl-3-butynoate (2-OB) (49), acetaminophen metabolites and related analogues (31) and
4-iodo-6-phenylpyrimidine (4IPP) (50). 2-OB also was shown to modify the catalytic N-
terminal proline of 4-oxalo-crotonate tautomerase (4-OT), a member of the tautomerase
superfamily that shares structural and functional similarities with MIF. Herein we also show
that irreversible modification of MIF by BITC abolished MIF tautomerase activity, reduced
MIF binding to the CD74 receptor and resulted in significant reduction in MIF-induced Akt
phosphorylation. Different alkyl and arylalkyl ITCs were shown to exhibit similar effects,
suggesting that the inhibitory effect of ITCs is mediated by the reactive isothiocyanate
group. Although ITCs are known to react with lysine and cysteine residues, MIF contains
three cysteines and three lysine residues per monomer; using proteolytic digestion and
peptide mapping we did not observe any modifications at these residues and could only
identify modifications at Pro1. These results can be explained by the fact that the pKa of
Pro1 is reduced by 5 pH units (27), making it the most nucleophilic residue at physiological
pH.
Isothiocynates (ITCs) are abundant in cruciferous vegetables (e.g., broccoli, kale, brussel
sprouts, cabbage, mustard, garden cress, cauliflower, and water cress). Epidemiological
studies have shown that consumption of high levels of ITCs may protect against lung, colon,
and other types of inflammation-related carcinogenesis, including skin cancer (51). ITCs,
including BITC, have also been shown to inhibit cell proliferation, induce cell cycle arrest
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and apoptosis, and exhibit anti-cancer properties in different animal and cellular models of
cancer (51-55).
To elucidate the molecular and structural basis underlying the inhibitory effect of BITC, we
performed detailed biochemical, biophysical, and structural studies to determine the effect of
Pro1 modification by BITC and other ITCs on the conformational state, quaternary
structure, enzymatic activity, receptor binding and biological properties of MIF. Together,
our results demonstrate that covalent modification of Pro1 by BITC and other ITCs result in
significant changes in the tertiary, but not the quaternary, structure of the MIF trimer. NMR
studies show that BITC induces drastic effects on the tertiary structure of MIF, in particular
residues (3-4, 32, 35-39, 49-50, 58-67, 79, 84-89, 95-97, 103, 107-109, and 112-114) that
cluster around Pro1 and constitute the tautomerase active site (Figure 7C), which explains its
diminished tautomerase activity. BITC-modified MIF exists predominantly as a single
specie corresponding to the trimer (by SEC, AUC, and light scattering) and eluted in SEC as
a single peak at 28 min, whereas the unmodified protein elutes as a mixture of two
overlapping peaks at 31 min and 33 min, both corresponding to the MIF trimer. These
changes in tertiary structure translated into a reduction of MIF biological activities, among
which binding to CD74 MIF receptor, MIF overriding of glucocorticoid-mediated inhibition
of TNF production by macrophages and MIF-induced Akt phosphorylation in HeLa cells.
Conformational changes, rather than loss of catalytic activity, may explain the biological
consequences of modifying the catalytic activity of MIF
Although, the relationship between the enzymatic and biological activity of MIF remains
unclear (32, 56), several small-molecule inhibitors of MIF tautomerase activity have been
shown to protect against the proinflammatory effects of MIF in vitro and in vivo (28, 33,
34). These findings have been used to support the hypothesis that the tautomerase activity of
MIF plays a direct role in modulating its biological activities in vivo. However, several lines
of evidence argue against this hypothesis and suggest that inhibition of MIF tautomerase
activity is not sufficient to abolish its proinflammatory function: 1) several catalytically
inactive mutants of MIF retain their proinflammatory activity in vitro; 2) C-terminal deletion
of the C-terminal 5-10 amino acid (residues 104-114) abolishes the catalytic activity of MIF
without affecting its binding to the receptor CD74 (43) which plays a key role in modulating
the signal transduction activity of MIF; 3) the catalytically inactive P1G mutants retains its
binding to the MIF cell surface receptor (CD74) and intracellular binding protein JAB1/
CSN5, albeit with some loss of affinity (56); 4) studies on the P1G-MIF knock-in mice
(mifP1G/P1G) demonstrate that the tautomerase activity of MIF is not essential for its growth-
regulatory properties (56).
These two hypotheses can be reconciled by the possibility that small molecule interactions
and/or covalent modification of the active site induce conformational or quaternary
structural changes that modify protein-protein interactions that mediates MIF biochemical
and biological properties. Given that MIF is trimeric, it is reasonable to consider that
changes in the oligomerization state of the protein may underlie its multifunctional
properties. To date, however, all the X-ray structure studies and in solution characterization
of MIF using different techniques reveal that MIF exists as a stable trimer and no evidence
for a stable dimeric or monomeric MIF have been reported. It is noteworthy that the
concentration of native MIF is in the range of 4-16 nM. Therefore, we can not rule out that
there is substantial amount of monomeric MIF under physiological conditions. Although our
data suggest that the monomer is unstable and has high propensity to aggregates, it is
possible that under physiological conditions the monomer is stabilized by its interactions
with small molecules, peptides or proteins in the cell.
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We propose that the conformational, rather than quaternary structure, heterogeneity of MIF
plays a role in modulating its protein-protein interaction, biochemical and biological activity
and underlie it multifunctionality. This hypothesis is consistent with recent studies from our
group demonstrating that the MIF trimer in solution exists in two different conformational
states that differ primarily at the level of tertiary structure (El-Turk et al, unpublished data).
These solution studies are supported by recent X-ray crystallography studies of the two
Leishmania major orthologues of MIF (LmjMIF1 and LmjMIF2) (57). Both LmjMIF and
LmjMIF2 crystalize in a trimeric form similar to that of mammalian MIF, but only
LmjMIF1 is enzymatically active. Comparison of the X-ray structure revealed subtle
structural differences between the two isoforms, mainly in the N-terminal region comprising
residues 30-37. Interestingly, C-terminal mutations that abolish the catalytic activity of MIF
favour the formation of a trimeric conformation that is distinct from those populated by the
wild type protein (43). Studies by Bucala and colleagues demonstrated that covalent
modification or mutation of Pro1 induces structural changes at the N-terminus that alters its
recognition by monoclonal antibodies and results in significant reduction of MIF cell surface
binding activity (31). These findings demonstrate that MIF is capable of adopting different
trimeric states that seem to differ primarily at the levels of tertiary structure, catalytic
activity and receptor binding activity.
Previously, we showed that C-terminal deletion mutants (ΔC5 huMIF1-109 and ΔC10
huMIF1-104) and a mutant in which the secondary structure of the C-terminal region
comprising residues 104-114 has been disrupted by the insertion of proline at position 107
(P107 huMIF) are catalytically inactive and elute as a single trimeric peak which elutes
earlier than the unmodified protein. Unlike, the BITC modified MIF; all the C-terminal
deletion mutants (ΔC5 huMIF1-109, and ΔC10 huMIF1-104) exhibited virtually identical
binding to CD74. These findings suggest that the C-terminal residues 105-114 may not be
directly involved in the binding to CD74 and further support a direct relationship between
the N-terminal region in modulating the structural properties and protein-protein interactions
mediating the biological activity of MIF. Together, our results combined with the lack of
data supporting the existence of a stable monomeric MIF highlight the role of tertiary
structure rather than quaternary structure in modulating the biochemical and biological
activities of MIF. At this stage, we can not role out a biological role for monomeric MIF in
vivo and the possibility that changes in the oligomerization state may also constitute a
molecular switch for modulating different functions of MIF.
Our observation that BITC and its analogs modify only enzymatically active conformations
of MIF and induces further conformational changes that alter MIF receptor binding
properties highlights the potential of new strategies for monitoring and/or modulating MIF’s
activity in health and disease. Conformational changes that alter the active site or pKa of the
catalytic proline residue appear to be sufficient for abolishing MIF reactivity toward BITC
and other ITCs. These results suggest that altering the catalytic site via selective
modification of the N-terminal proline residue may present new opportunities for
modulating MIF biological activities in vivo. More recently, Merk et al. also demonstrated
that covalent modification of Pro1 by 4-iodo-6-phenylpyrimidine (4-IPP) blocks MIF
secretion by influencing its interaction with p115, a Golgi complex associated protein
recently identified as a key partner of MIF and modulator of its secretion (58). A change in
the native conformation of MIF was proposed as a mechanism underlying the effect of 4-IPP
on MIF-p115 interaction, although the nature of this change was not investigated. These
findings are consistent with our results and demonstrate the possibility of regulating MIF’s
protein-protein interactions and activity by modulating its catalytic activity and suggest
different roles for the catalytic domain and tautomerase activity.
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CONCLUSION
We have shown that BITC and other ITCs are effective inhibitors of MIF tautomerase
activity. Although this inhibitory effect of ITCs is mediated by their covalent modification
of the catalytic N-terminal proline residue, their effect on MIF’s receptor binding and
proinflammatory activity is in part mediated by changes in the tertiary structure of MIF as a
result of modifying the N-terminus and/or catalytic site. The design of novel active site-
directed irreversible inhibitors based on structural complementarily with the catalytic active
site and incorporation of reactive groups should yield novel mechanism-based inhibitors of
MIF biological activities. Furthermore, the specificity and selectivity of BITC reactivity
with Pro1, as a consequence of its low pKa, also opens new opportunities for specific
labeling of MIF and monitoring of its activity in vivo. For example, MIF reactivity with
ITCs could be used as an indirect method to quantify the ratio of active/inactive MIF trimers
in biological samples, which might provide a better correlation with disease progression and
severity than total MIF levels.
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Abbreviations
MIF macrophage migration inhibitory factor
ITC Isothiocyanate
BITC Benzyl isothiocyanate
AITC allyl isothiocyamate
EITC ethyl isothiocyanate
MITC methallyl isothiocyanate
2-2PITC Piperidinoethyl isothiocyanate
CPITC Cyclopropyl isothiocyanate
PEITC Phenylethyl isothiocyanate
CD circular dichroism
SEC size-exclusion chromatography
AUC analytical ultracentrifugation
MALDI matrix-assisted laser desorption ionization
HSQC heteronuclear single quantum coherence
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FIGURE 1.
Trimer formation is required for MIF tautomerase activity. (A) Ribbon diagram showing the
MIF homotrimer and the tatuomerase active site. Each monomer is indicated by a different
color. The figure was generated using VMD software and the pdb file 1GDO has a
resolution of 1.5 A. The MIF catalytic site complexed with (E)-2-fluoro-p-hydroxycinnamic
acid indicates that the molecules interact through the side chains of Pro1, Lys32 and Asn97
from two neighboring subunits. (B) Mechanism of MIF tautomerase reaction as proposed by
Stamps et al., 2000.
Ouertatani-Sakouhi et al. Page 16
Biochemistry. Author manuscript; available in PMC 2013 March 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 2.
Several isothiocyanate-based compounds inhibit MIF tautomerase activity in a concentration
dependent manner. IC50s concentration response curve (mean +/− SD; n=8) obtained by
monitoring initial velocity of HPP Keto form tautomirization to HPP enol form by MIF.
MIF 100 nM was preincubated with different concentrations of ITC analogues BITC, AITC,
EITC, MITC and 2PITC for 5 min, followed by the addition of 2 mM
Hydroxyphenylpuryvate, then absorbance was monitored at 300 nm for 5 min. Initial
velocity was calculated and normalized to percentage of activity.
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FIGURE 3.
BITC and other isothiocyanate based MIF inhibitors covalently modify the catalytic N-
terminal proline residue (Pro1). (A) MIF was incubated in the presence or absence of BITC
or one of its analogues (10 μM) for 30 min, and the samples were then prepared using
senapinic acid as a matrix and analyzed by MALDI-TOF/TOF in linear positive ions mode.
(B) MIF was incubated with 10 μM BITC for 60 min and digested with Trypsin 1/50 ON at
37 °C at pH 8. After being desalted, the samples were analyzed by MS. (C) Schematic
depiction of the chemical reaction leading to the formation of a covalent adducts between
Pro1 of MIF and BITC.
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FIGURE 4.
Only enzymatically active forms of the MIF trimer undergo covalent modification by BITC
and its active analogues. Six trimeric MIF variants (3 enzymatically active: Wt, R73A, and
N110C, and 3 inactive: R73AΔ5, R73AΔ10, and P107) were tested by incubation with 10
μM BITC for 60 min, and the samples were then analyzed by MALDI-TOF/TOF.
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FIGURE 5.
Covalent modification of MIF by BITC does not affect its oligomerization state.
Sedimentation velocity profiles of MIF in the presence or absence of BITC. MIF (10 μM) in
PBS was preincubated with 6 μM BITC for 1 h at RT. Sedimentation coefficient
distributions were obtained by analysis of the sedimentation profiles using the C (s)
distribution as a variant of Lamm equation solutions. Calculations were performed using
Sedfit software (www.sedfit.com).
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FIGURE 6.
ITC modification of MIF stabilizes a trimeric form that is distinct from those adopted by the
wild type protein. MIF alone (solid line) and MIF incubated (dashed line) with 10 μM of
MITC (A), 2PITC (B), AITC (C), BITC (D) and EITC (E) were injected into an analytical
Superdex 75 column and analyzed by light scattering upon elution. The individual data
points show the molecular weight at each point in the chromatogram. Measurements were
performed at protein concentration of 10 μM, in PBS 1X, pH 7.4.
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FIGURE 7.
Covalent modification of Pro1 by BITC induces drastic changes in the tautomerase active
site of MIF. (A) Superimposed contour plots of the 1H-15N HSQC spectra of 15N-labeled
MIF in the free state (black) and for an equimolar mixture of MIF and BITC (red) measured
at 27°C. Addition of BITC to MIF results in severe resonance broadening. (B) Changes in
individual cross-peak intensities of MIF (100 μM) upon addition of 50 μM (grey) and 100
μM (red) BITC. (C) Residues affected upon addition of BITC mapped into the crystal
structure of the MIF homotrimer (pdb file 1GDO). Residues that are affected cluster around
P1 (red). The two views are related to each other by an angle of 90°.
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FIGURE 8.
ITC based inhibitors of MIF tautomerase activity interfere with MIF binding to its receptor,
CD74. (A). Dose-dependent inhibition by the isothiocyante derivative BITC, AITC, EITC,
MITC, and 2PITC. Test compounds were pre-incubated with 2ng/μl of 0.2 μM biotinylated
MIF equal to 0.16 μM for 2 h at room temperature in the dark prior to addition to 96 well
plates pre-coated with recombinant human sCD74. Data points are the mean of duplicate
determinations of bound MIF.
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FIGURE 9.
Effect of BITC on MIF-mediated glucocorticoid overriding activity (A) and Akt
phosphorylation (B). (A) Human macrophages were preincubated for 1 h with (+) or without
(−) dexamethasone (Dex 100 nM), MIF (100 ng/mL) and BITC (10 μM) before stimulation
with LPS (100 ng/mL). Cell-free supernatants were collected after 4 h to quantify the
concentrations of TNF. Data are means ± SD of triplicate samples from one experiment and
are representative of four independent experiments. Statistical analyses were performed
using one way Anova followed by Scheffè’s test. ** p < 0.001. (B) BITC inhibits MIF-
induced activation of Akt phosphorylation. HeLa cells were incubated for 2 h with 50 ng/mL
MIF in the presence or the absence of 1-10 μM BITC and LY294002 (a selective inhibitor
of the PI3K/Akt pathway). Akt phosphorylation was quantified using the Alpha screen
SureFire phosphokinase KIT as described in Materials and Methods. Data are expressed as
Alpha screen counts per mg of total protein means ± SD of triplicate samples from one
experiment and representative of 2 independent experiments. Statistical analyses were
performed using one way Anova followed by Scheffè test. * p < 0.05
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